Omeros Corporation (OMER)

Omeros' stock experienced a surge after announcing a deal with Novo Nordisk for zaltenibart in October 2025. The stock declined sharply in May 2025 after announcing agreements to acquire convertible senior notes due in 2026. The regulatory path for narsoplimab has been a recurring factor, with the FDA accepting the BLA resubmission with an extended PDUFA date.

There is no direct indication of demand seasonality for Omeros Corp.'s products and services. Demand is primarily driven by medical need, disease prevalence, and regulatory approvals, rather than seasonal fluctuations. The company's revenue model relies on royalties and potential milestone payments, which are not typically subject to seasonal demand patterns.

Omeros Corp. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics for unmet medical needs in complement-mediated diseases, inflammation, central nervous system disorders, cancers, and addictive/compulsive disorders. Key products and pipeline candidates include Narsoplimab (OMS721), a MASP-2 inhibitor under regulatory review for HSCT-TMA and investigated for other conditions; Zaltenibart (OMS906), a MASP-3 inhibitor with global rights acquired by Novo Nordisk for rare blood and kidney disorders; OMS1029, a long-acting MASP-2 inhibitor in Phase 1 trials; OMS527, a PDE7 inhibitor for cocaine use disorder; and OMIDRIA, a previously approved ophthalmic drug sold to Rayner Surgical, with Omeros retaining royalty income.

Omeros Corporation is headquartered in Seattle, Washington, United States. While the company develops products for global markets, Novo Nordisk has exclusive global rights for the development and commercialization of zaltenibart.

Omeros Corporation's brand reputation has been influenced by clinical development progress and financial stability. The Novo Nordisk deal for zaltenibart and positive clinical data for narsoplimab had positive impacts. Prior to the deal, the company faced challenges including financial losses, unmet expectations, and concerns about liquidity, as well as the prolonged regulatory process for narsoplimab, which negatively impacted its reputation.

Omeros Corporation's ownership includes institutional investors, company insiders, and the general public. Institutional investors hold a significant portion of the shares, with major holders including BlackRock, Inc., Ingalls & Snyder Llc, and Vanguard Group Inc. Company insiders, including Chairman & CEO Gregory Demopulos, hold approximately 3.88% to 8% of the company. Individual retail investors and other entities hold the remaining shares.